ArticleJournal of cosmetic dermatology2025
Real World Case Series: A.G.E. Interrupter Ultra Serum.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-Associated Differences in Facial Skin Structure in Chinese Women: a Cross-Sectional Study.Dermatology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe A.G.E. Interrupter serum has been developed in an oil-in-water emulsion to contain 30% proxylane, Cassia alata extract, blueberry and pomegranate extract, rhamnose, and gentiana lutea root extract. The technology has several patent ingredients as well as synergistic patents with proxylane, rhamnose, and new ones submitted for the new ingredients. An ex vivo model using this final formulation has shown upregulation of laminin-5, collagen IV, tropoelastin, and collagen III. Collagen IV and laminin are present in the dermal-epidermal junction (DEJ) and are factors in the basement membrane function. Over time, the DEJ decreases in height and in surface area, leading to weakened skin integrity and structure. The serum was tested to illustrate visible life in the jawline, forehead, cheek, and neck as well as instrumental testing showing visible improvement in the nasolabial fold and forehead wrinkle.
aimTo present a real-world case series that demonstrates the use of the A.G.E. Interrupter serum as an adjunctive therapy to collagen-stimulating procedures in a wide variety of patient ages and skin types.
methodsEight internationally recognized, licensed dermatologists with extensive experience in cosmetic and facial rejuvenation procedures were selected to participate in an expert panel. During the expert panel, dermatologists were asked to share 2 cases using the A.G.E. Interrupter serum in patients undergoing collagen-stimulating procedures.
resultsFollowing the panel discussion, seven patient cases were selected to illustrate the use of the A.G.E. Interrupter serum in conjunction with collagen-stimulating procedures to optimize patient outcomes and satisfaction. Experts found that daily A.G.E. Interrupter serum application post-procedure led to improved overall results and high patient satisfaction.
conclusionThis case series provides evidence for different integrated skincare regimens using the A.G.E. Interrupter serum in a variety of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.